Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

NCT: NCT06662162 · RECRUITING

NCT IDNCT06662162
StatusRECRUITING
Start Date2025-05-07
Completion2029-12-31

Brief Summary

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD. Participants will: * Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months. * Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.

Frequently Asked Questions

What is Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration?

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration is a clinical trial registered under NCT06662162. Current status: RECRUITING.

What is the status of NCT06662162?

The current status of NCT06662162 (Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration) is: RECRUITING.

When did Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration start?

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration started on 2025-05-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑